Escalon Medical Corp. reports that a long-standing material weakness in its internal control over inventory valuation remains unremediated as of June 30, 2026.
SEC EDGAR, 2026-10-13: 10-K — "material weakness"
Escalon Medical Corp. reports that a long-standing material weakness in its internal control over inventory valuation remains unremediated as of June 30, 2026.
Company: ESCALON MEDICAL CORP (ESMC) Filed: 2026-10-13, 10-K Phrase: "material weakness" — "The Company has identified a material weakness in its internal control over financial reporting, which could result in material misstatements in the Company’s financial statements." What the filing says: In its annual report for the fiscal year ended June 30, 2026, the company disclosed that it continues to have an unremediated material weakness in its internal control over financial reporting. The weakness, first identified during the fiscal year ended June 30, 2023, relates to the design and implementation of controls over estimates used in the valuation of inventory, specifically the precision of management’s review of inventory reserve calculations. Although the company has implemented additional controls since the fourth quarter of fiscal 2024, the inventory reserve spreadsheet continues to rely on manual entries that management's review does not fully cover, and testing of the operating effectiveness of the enhanced controls has not been completed. Two ways it goes: A. The company successfully tests and implements its enhanced controls to remediate the material weakness. B. The unremediated control weakness leads to material misstatements in the company's financial reports or requires restatements of previously issued financial statements. Next date: none named Watch: Future quarterly and annual reports on Form 10-Q and Form 10-K showing whether testing of the operating effectiveness of the enhanced controls has been completed and the weakness remediated.